hostile takeover | GenomeWeb

hostile takeover

NEW YORK (GenomeWeb News) – Following notification by a hedge fund headed by Carl Icahn of its intentions to acquire a stake in Hologic, the Bedford, Mass.-based firm today announced it has adopted a stockholder rights plan "intended to ensure that the board remains in the best position to perfor

This article has been updated with comments from an internal Illumina e-mail.
By a GenomeWeb staff reporter

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Roche today reported that its molecular diagnostics sales increased 4 percent year over year, while its sales for microarrays and genomic sequencing products dropped sharply.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Institutional Shareholder Services, a proxy-advisory firm, today recommended that Illumina's shareholders vote against Roche's slate of nominees for Illumina's board of directors.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) — In its pursuit to acquire Illumina in a hostile takeover, Roche has again turned directly to the company's shareholders, aiming to convince them of the attractiveness of its offer.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Illumina has once again rejected Roche's offer to acquire the firm and is urging its shareholders to also reject Roche's slate of nominees for Illumina's board of directors.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Roche said today that is has raised its cash tender offer for Illumina from $44.50 to $51 per share — an increase of 15 percent — valuing the deal at nearly $6.7 billion.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Roche has extended its $5.7 billion hostile takeover bid for Illumina for another month at the same price, the company said today.

Pages

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.